SILVER SPRING, Md., Sept. 5, 2024 /PRNewswire/ — September is National Food Safety Education Month. The U.S. Food and Drug Administration (FDA) focuses on the importance of food safety, especially for those more vulnerable to foodborne illnesses, commonly known as food poisoning. By following four simple steps—clean, separate, cook, and chill—you can lower the risk of getting sick. Discover more about the dangers of foodborne illnesses, and how to protect those at higher risk of getting sick below.
Groups at High-Risk of Foodborne Illness
Every year, 1 in 6 Americans gets sick from foodborne illnesses. Foodborne illnesses also result in an estimated 128,000 hospitalizations and 3,000 deaths yearly. Some groups of people are at greater risk of getting a foodborne illness or experiencing one for longer, require hospitalization, or even die. These groups include:
Foods Associated with Higher Risk for Foodborne Illness
If you or your loved ones are at a high-risk of foodborne illness, reduce the risk by knowing which foods are associated with higher risk:
Review the FDA’s complete list of higher risk foods.
Symptoms of Foodborne Illnesses
If you eat contaminated food, symptoms of foodborne illness appear 12 to 72 hours later, but they may occur between 30 minutes and 4 weeks later. Symptoms can include:
You should contact your physician or health care provider as soon as possible if you suspect you may have a foodborne illness.
To keep you and your family safer from food poisoning, follow these four simple steps:
To learn more about each safe food handling step, visit:
https://www.fda.gov/food/buy-store-serve-safe-food/safe-food-handling
For more information for people at high-risk for foodborne illness, visit: https://www.fda.gov/food/consumers/people-risk-foodborne-illness
For more information about National Food Safety Education Month, visit:
https://www.fda.gov/food/consumers/food-safety-education-month
Contact: Media: 1-301-796-4540 Consumers: 1-888-SAFEFOOD (toll-free)
SOURCE U.S. Food and Drug Administration
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…